WASHINGTON — The Trump administration, which in recent months had avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.
Speaking from the Oval Office, Presiden...
Subscribe to STAT’s news feed.
Click on “Follow” and decide if you want to get news from STAT via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to STAT comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from STAT which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: STAT | Reporting from the frontiers of health and medicine
Is this your feed? Claim it!
WASHINGTON — The Trump administration, which in recent months had avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.
Speaking from the Oval Office, Presiden...
The Food and Drug Administration has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.
The drug, ITM-11, had been developed by ITM Isotope Technologies Munich SE, a long-standing player in the field. Radiopharmaceuticals are an
WASHINGTON — The Department of Health and Human Services on Monday announced a new effort to catalog the many additives in the U.S. food supply, most of which entered with little oversight.
Companies looking to add a new substance to human or animal foods will need to notify the Food and Drug Administration, and provide details on how they deemed the additive “gene...
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.
The cyclosporiasis outbreak means a lot of poop has been tested. Spare a thought for the lab professionals who are
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Radiopharma’s precision promise runs into toxicity problems, China puts new guardrails around its biotech innovation engine, and Grail’s...